{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b65e1af7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: openai in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (1.91.0)\n",
      "Requirement already satisfied: python-docx in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (1.2.0)\n",
      "Requirement already satisfied: requests in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (2.32.3)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (4.8.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (1.9.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (0.28.1)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (0.10.0)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (2.11.3)\n",
      "Requirement already satisfied: sniffio in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (1.3.1)\n",
      "Requirement already satisfied: tqdm>4 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (4.67.1)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.11 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from openai) (4.12.2)\n",
      "Requirement already satisfied: exceptiongroup>=1.0.2 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from anyio<5,>=3.5.0->openai) (1.2.2)\n",
      "Requirement already satisfied: idna>=2.8 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from anyio<5,>=3.5.0->openai) (3.10)\n",
      "Requirement already satisfied: certifi in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from httpx<1,>=0.23.0->openai) (2025.1.31)\n",
      "Requirement already satisfied: httpcore==1.* in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from httpx<1,>=0.23.0->openai) (1.0.7)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.33.1 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from pydantic<3,>=1.9.0->openai) (2.33.1)\n",
      "Requirement already satisfied: typing-inspection>=0.4.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from pydantic<3,>=1.9.0->openai) (0.4.0)\n",
      "Requirement already satisfied: lxml>=3.1.0 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from python-docx) (5.4.0)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from requests) (3.4.1)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/parakhagrawal/.pyenv/versions/3.10.12/lib/python3.10/site-packages (from requests) (2.3.0)\n"
     ]
    }
   ],
   "source": [
    "!pip install openai python-docx requests\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5938fb59",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Access token received\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from storage import upload_file\n",
    "\n",
    "# GSK OAuth URL and client credentials\n",
    "token_url = \"https://federation-qa.gsk.com/as/token.oauth2\"\n",
    "client_id = \"eb98c3a954444f91a887dc054dd2037c\"\n",
    "client_secret = \"XJJVX1bKrQ1YznWfzHunzVhTkQJP2I3wivNjBG2k2rJlHQNIDVV1AwL7TABtAZtcaMF4\"\n",
    "\n",
    "# Request token\n",
    "response = requests.post(\n",
    "    token_url,\n",
    "    data={\n",
    "        \"grant_type\": \"client_credentials\",\n",
    "        \"client_id\": client_id,\n",
    "        \"client_secret\": client_secret\n",
    "    }\n",
    ")\n",
    "\n",
    "# Parse token\n",
    "access_token = response.json()[\"access_token\"]\n",
    "print(\"‚úÖ Access token received\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "fd1c35c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# GSK Enterprise OpenAI Endpoint\n",
    "endpoint = \"https://dev.api.gsk.com/co/edap/openaidevtest02/openai/deployments/gpt-4o/chat/completions?api-version=2025-01-01-preview\"\n",
    "\n",
    "# Headers with OAuth token\n",
    "headers = {\n",
    "    \"Authorization\": f\"Bearer {access_token}\",\n",
    "    \"Content-Type\": \"application/json\"\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "00c8a2e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def summarize_field(field, matched_paragraph):\n",
    "    prompt = f\"\"\"\n",
    "You are an AI assistant generating a summary for a clinical report.\n",
    "\n",
    "Summarize the following paragraph as a proper response to the field '{field}'.\n",
    "\n",
    "For numerical fields, only return numbers. \n",
    "\n",
    "Paragraph:\n",
    "{matched_paragraph}\n",
    "\n",
    "Summary:\n",
    "\"\"\"\n",
    "\n",
    "    # Prepare payload\n",
    "    payload = {\n",
    "        \"messages\": [\n",
    "            {\"role\": \"user\", \"content\": prompt}\n",
    "        ],\n",
    "        \"temperature\": 0.5\n",
    "    }\n",
    "\n",
    "    # Send request to GSK OpenAI endpoint\n",
    "    response = requests.post(endpoint, headers=headers, data=json.dumps(payload))\n",
    "    result = response.json()\n",
    "\n",
    "    return result[\"choices\"][0][\"message\"][\"content\"].strip()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "50a53433",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "# Load matched_paragraphs from semantic_matching.json (from Day 2 output)\n",
    "with open(\"matched_paragraphs.json\", \"r\") as f:\n",
    "    matched_paragraphs = json.load(f)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "ea503178",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üü© FIELD: Protocol Summary - Master Disclosure Document for Interventional Studies\n",
      "üîç Matched Paragraph:\n",
      " 6.\tSTUDY INTERVENTION(S) AND CONCOMITANT THERAPY\t46\n",
      "üìù Summary:\n",
      " Study Interventions: 6  \n",
      "Concomitant Therapy: 46\n",
      "\n",
      "üü© FIELD: The Information on this page will not be posted\n",
      "üîç Matched Paragraph:\n",
      " PAGE\n",
      "üìù Summary:\n",
      " The information provided on this page is not intended for publication or sharing.\n",
      "\n",
      "üü© FIELD: Before using this template for authoring, refer to the supplemental instructions on Find-IT. This template is used for ALL Interventional studies that evaluate the safety, efficacy or effectiveness of a GSK product.\n",
      "Master Disclosure Document (MDD) serves as the source document to disclose protocol related information across different clinical trial registers (e.g. ClinicalTrials.gov, EU Clinical Trials Information System (EU CTIS) and/or GSK/ViiV Clinical Study Register) as required by external regulations and/or GSK policy. Check in TMF for the latest version of the template before initiating a new MDD. As information from the approved MDD will be disclosed on publicly available clinical trial register(s) as required by applicable regulations and GSK policy, minimize inclusion of information that may be considered commercially confidential.\n",
      "üîç Matched Paragraph:\n",
      " The key design elements of this protocol and results summaries will be posted on www.ClinicalTrials.gov and/or GSK Clinical Study Register in compliance with applicable regulations/GSK policy. GSK will aim to register protocols summaries prior to study start and target results summaries submission within 12 months of primary/ study completion date. Where external regulations require earlier disclosure, GSK will follow those timelines.\n",
      "üìù Summary:\n",
      " Key design elements and results summaries will be disclosed on www.ClinicalTrials.gov and/or GSK Clinical Study Register per regulations/GSK policy. Protocol summaries are targeted for registration prior to study start, and results summaries submission is aimed within 12 months of primary/study completion. Earlier disclosure timelines will be followed if required by external regulations.\n",
      "\n",
      "üü© FIELD: Title of study\n",
      "üîç Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "üìù Summary:\n",
      " Title of study: Observational study analyzing clinical outcomes and treatment efficacy in a patient cohort.\n",
      "\n",
      "üü© FIELD: Study identifier /CTMS number\n",
      "üîç Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "üìù Summary:\n",
      " This section does not provide specific numerical identifiers like CTMS numbers. Please ensure the correct field is referenced.\n",
      "\n",
      "üü© FIELD: European Union (EU) Clinical Trial Regulation (EU CTR) number (if applicable)\n",
      "üîç Matched Paragraph:\n",
      " Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulation (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n",
      "üìù Summary:\n",
      " 536/2014\n",
      "\n",
      "üü© FIELD: Is this an Applicable Clinical Trial (ACT)?\n",
      "üîç Matched Paragraph:\n",
      " The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).\n",
      "üìù Summary:\n",
      " Yes, this is an Applicable Clinical Trial (ACT).\n",
      "\n",
      "üü© FIELD: Trial registers where the study will be disclosed\n",
      "üîç Matched Paragraph:\n",
      " STUDY ASSESSMENTS AND PROCEDURES\n",
      "üìù Summary:\n",
      " Trial registers where the study will be disclosed: The study will be registered on ClinicalTrials.gov and the European Union Clinical Trials Register (EudraCT).\n",
      "\n",
      "üü© FIELD: MDD version date\n",
      "üîç Matched Paragraph:\n",
      " Dates of administration including start and end dates\n",
      "üìù Summary:\n",
      " Start and end dates of administration.\n",
      "\n",
      "üü© FIELD: Approver:\n",
      "üîç Matched Paragraph:\n",
      " 10.1.3.\tInformed consent process\t69\n",
      "üìù Summary:\n",
      " Approver: 69\n",
      "\n",
      "üü© FIELD: Clinical Lead/equivalent\n",
      "üîç Matched Paragraph:\n",
      " Participant safety will be continuously monitored by the Sponsor‚Äôs Medical Monitor, and designated Safety Lead (or delegate) throughout the study. Pertinent findings and conclusions are shared with the product‚Äôs safety review team for review of the overall benefit-risk profile of the product.\n",
      "üìù Summary:\n",
      " The Sponsor‚Äôs Medical Monitor and designated Safety Lead (or delegate) will oversee participant safety throughout the study, sharing relevant findings with the safety review team to evaluate the product's benefit-risk profile.\n",
      "\n",
      "üü© FIELD: Section # and Name of the field\n",
      "{Add section number and name}\n",
      "üîç Matched Paragraph:\n",
      " Medical Monitor Name and Contact Information:\n",
      "üìù Summary:\n",
      " Section # and Name of the field  \n",
      "{Medical Monitor Name and Contact Information}\n",
      "\n",
      "üü© FIELD: Unique Protocol ID\n",
      "üîç Matched Paragraph:\n",
      " Protocol Title:\n",
      "üìù Summary:\n",
      " Protocol Title\n",
      "\n",
      "üü© FIELD: Brief title\n",
      "üîç Matched Paragraph:\n",
      " Brief Title:\n",
      "üìù Summary:\n",
      " Summary of Clinical Report\n",
      "\n",
      "üü© FIELD: Acronym\n",
      "üîç Matched Paragraph:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS\n",
      "üìù Summary:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS\n",
      "\n",
      "üü© FIELD: CTMS abbreviated title [EU only]\n",
      "üîç Matched Paragraph:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS\n",
      "üìù Summary:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS\n",
      "\n",
      "üü© FIELD: Official title of the trial\n",
      "üîç Matched Paragraph:\n",
      " Brief Title:\n",
      "üìù Summary:\n",
      " Please provide the paragraph you would like summarized for the field \"Official title of the trial.\"\n",
      "\n",
      "üü© FIELD: Secondary IDs\n",
      "üîç Matched Paragraph:\n",
      " Secondary estimands\n",
      "üìù Summary:\n",
      " Secondary estimands refer to additional measures or analyses that complement the primary estimand in a clinical study. These may provide further insights into treatment effects, subpopulations, or alternative endpoints.\n",
      "\n",
      "üü© FIELD: Secondary ID type\n",
      "üîç Matched Paragraph:\n",
      " Secondary estimands\n",
      "üìù Summary:\n",
      " Secondary ID type: Secondary estimands\n",
      "\n",
      "üü© FIELD: Sponsor\n",
      "üîç Matched Paragraph:\n",
      " Sponsor Signatory:\n",
      "üìù Summary:\n",
      " The paragraph does not provide specific information about the sponsor. Please provide additional details for an accurate summary.\n",
      "\n",
      "üü© FIELD: Collaborators\n",
      "üîç Matched Paragraph:\n",
      " Activity\n",
      "üìù Summary:\n",
      " Collaborators: The section does not provide specific information regarding collaborators.\n",
      "\n",
      "üü© FIELD: Brief summary\n",
      "üîç Matched Paragraph:\n",
      " Brief Title:\n",
      "üìù Summary:\n",
      " Brief summary: No information provided.\n",
      "\n",
      "üü© FIELD: Detailed description\n",
      "üîç Matched Paragraph:\n",
      " Synopsis\n",
      "üìù Summary:\n",
      " Please provide the paragraph you'd like summarized, and I will generate a concise summary for the \"Detailed description\" field.\n",
      "\n",
      "üü© FIELD: Main objective(s) [EU only]\n",
      "üîç Matched Paragraph:\n",
      " Objectives, Endpoints, and Estimands:\n",
      "üìù Summary:\n",
      " To evaluate the efficacy, safety, and tolerability of the investigational product in the target population, focusing on predefined clinical endpoints and estimands to measure treatment outcomes.\n",
      "\n",
      "üü© FIELD: Secondary objective(s) [EU only]\n",
      "üîç Matched Paragraph:\n",
      " OBJECTIVES, ENDPOINTS AND ESTIMANDS\n",
      "üìù Summary:\n",
      " Secondary objective(s) [EU only]: Identify additional clinical endpoints and estimands to evaluate secondary outcomes beyond the primary objective.\n",
      "\n",
      "üü© FIELD: Data monitoring committee\n",
      "üîç Matched Paragraph:\n",
      " Data Monitoring/Other Committee:\n",
      "üìù Summary:\n",
      " The Data Monitoring Committee oversees patient safety and study integrity, reviews interim data, and provides recommendations for trial continuation, modification, or termination.\n",
      "\n",
      "üü© FIELD: Keywords\n",
      "üîç Matched Paragraph:\n",
      " REFERENCES\n",
      "üìù Summary:\n",
      " Keywords: References, citations, literature, sources\n",
      "\n",
      "üü© FIELD: Medical condition(s) investigated [EU only]\n",
      "üîç Matched Paragraph:\n",
      " Abnormal laboratory findings associated with the underlying disease are not considered clinically significant unless judged by the Investigator to be more severe than expected for the participant‚Äôs condition.\n",
      "üìù Summary:\n",
      " Abnormal laboratory findings related to the underlying disease, unless deemed unusually severe by the Investigator, are not considered clinically significant.\n",
      "\n",
      "üü© FIELD: Therapeutic area [EU only]\n",
      "üîç Matched Paragraph:\n",
      " Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulation (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n",
      "üìù Summary:\n",
      " Therapeutic area [EU only]: Adherence to European regulation 536/2014 for clinical studies and applicable local regulations.\n",
      "\n",
      "üü© FIELD: Rare disease [EU only]\n",
      "üîç Matched Paragraph:\n",
      " Abnormal laboratory findings associated with the underlying disease are not considered clinically significant unless judged by the Investigator to be more severe than expected for the participant‚Äôs condition.\n",
      "üìù Summary:\n",
      " Abnormal laboratory findings related to the underlying rare disease are not deemed clinically significant unless the Investigator determines they exceed the expected severity for the participant's condition.\n",
      "\n",
      "üü© FIELD: Primary purpose\n",
      "üîç Matched Paragraph:\n",
      " Reason for use\n",
      "üìù Summary:\n",
      " The primary purpose is to outline the reason for the clinical intervention or treatment.\n",
      "\n",
      "üü© FIELD: Study Phase\n",
      "üîç Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "üìù Summary:\n",
      " Phase 3\n",
      "\n",
      "üü© FIELD: Type of human pharmacology (Phase 1) study (EU only)\n",
      "üîç Matched Paragraph:\n",
      " Pharmacodynamics\n",
      "üìù Summary:\n",
      " Pharmacodynamics study.\n",
      "\n",
      "üü© FIELD: Interventional study model\n",
      "üîç Matched Paragraph:\n",
      " Study intervention(s) administered\n",
      "üìù Summary:\n",
      " The study utilizes a single-group interventional model where participants receive a specific intervention without a comparison group.\n",
      "\n",
      "üü© FIELD: Allocation\n",
      "üîç Matched Paragraph:\n",
      " Committees structure\n",
      "üìù Summary:\n",
      " Committees structure not relevant to 'Allocation'.\n",
      "\n",
      "üü© FIELD: Anticipated date of results (EU only)\n",
      "üîç Matched Paragraph:\n",
      " Table 6\tTimeframes for submitting SAE, pregnancy and other events reports to GSK\t63\n",
      "üìù Summary:\n",
      " 63\n",
      "\n",
      "üü© FIELD: Number of arms\n",
      "üîç Matched Paragraph:\n",
      " Number of Participants:\n",
      "üìù Summary:\n",
      " 1\n",
      "\n",
      "üü© FIELD: Masking type \n",
      "(EU only)\n",
      "üîç Matched Paragraph:\n",
      " Blinding/Masking\n",
      "üìù Summary:\n",
      " Masking Type: Blinded\n",
      "\n",
      "üü© FIELD: Masking description / Blinding implementation details\n",
      "üîç Matched Paragraph:\n",
      " Blinding/Masking\n",
      "üìù Summary:\n",
      " Blinding was implemented by ensuring that participants, investigators, and outcome assessors were unaware of group assignments throughout the study. Identical placebo and active treatments were used to maintain blinding. Randomization codes were securely stored and only revealed after data analysis was completed.\n",
      "\n",
      "üü© FIELD: Arms\n",
      "Repeat below rows depending on number of arms\n",
      "üîç Matched Paragraph:\n",
      " Exclusion criteria\n",
      "üìù Summary:\n",
      " Exclusion criteria are not relevant to the 'Arms' field. Please provide details specific to study arms for summarization.\n",
      "\n",
      "üü© FIELD: Arm / Group Label\n",
      "üîç Matched Paragraph:\n",
      " Not applicable as this is an open-label study.\n",
      "üìù Summary:\n",
      " Open-label study\n",
      "\n",
      "üü© FIELD: Arm / Group description\n",
      "üîç Matched Paragraph:\n",
      " The estimand is described by the following attributes:\n",
      "üìù Summary:\n",
      " The estimand is characterized by specific attributes relevant to the study's objectives and analysis.\n",
      "\n",
      "üü© FIELD: Interventions\n",
      "Repeat below rows depending on number of interventions\n",
      "üîç Matched Paragraph:\n",
      " Table 4\tStudy intervention administered.\n",
      "üìù Summary:\n",
      " Intervention: Study intervention administered.\n",
      "\n",
      "üü© FIELD: Intervention name\n",
      "üîç Matched Paragraph:\n",
      " Study intervention(s) administered\n",
      "üìù Summary:\n",
      " Study intervention(s) administered\n",
      "\n",
      "üü© FIELD: Intervention description\n",
      "üîç Matched Paragraph:\n",
      " Assignment to study intervention\n",
      "üìù Summary:\n",
      " Assignment to study intervention involved randomization of participants to receive either the experimental treatment or the control intervention, ensuring balanced allocation across groups.\n",
      "\n",
      "üü© FIELD: Other names\n",
      "üîç Matched Paragraph:\n",
      " REFERENCES\n",
      "üìù Summary:\n",
      " \"REFERENCES\" is not a proper response for the field 'Other names.' No relevant information is contained in the provided paragraph to summarize for this field.\n",
      "\n",
      "üü© FIELD: Relationship between Arms & Interventions\n",
      "Repeat below rows depending on number of arms)\n",
      "üîç Matched Paragraph:\n",
      " Table 4\tStudy intervention administered.\t48\n",
      "üìù Summary:\n",
      " Relationship between Arms & Interventions:  \n",
      "Study intervention administered: 48\n",
      "\n",
      "üü© FIELD: Arm\n",
      "üîç Matched Paragraph:\n",
      " APPENDIX\n",
      "üìù Summary:\n",
      " APPENDIX\n",
      "\n",
      "Arm: Not specified.\n",
      "\n",
      "üü© FIELD: Outcome measure type\n",
      "üîç Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "üìù Summary:\n",
      " Outcome measure type: The assessment included both qualitative measures, such as patient-reported outcomes and observational analyses, and quantitative measures, including numerical scores derived from standardized scales.\n",
      "\n",
      "üü© FIELD: Outcome measure title\n",
      "üîç Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "üìù Summary:\n",
      " Assessment of outcomes\n",
      "\n",
      "üü© FIELD: Outcome measure description\n",
      "üîç Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "üìù Summary:\n",
      " Assessment of outcomes involved evaluating changes in clinical parameters, patient-reported outcomes, and overall treatment efficacy using standardized scales and validated tools.\n",
      "\n",
      "üü© FIELD: Time frame\n",
      "üîç Matched Paragraph:\n",
      " * Timeframe allowed after receipt or awareness of the information by the Investigator/site staff.\n",
      "üìù Summary:\n",
      " 30 days\n",
      "\n",
      "üü© FIELD: Sex\n",
      "üîç Matched Paragraph:\n",
      " Activity\n",
      "üìù Summary:\n",
      " The paragraph provided does not contain information relevant to the field 'Sex.'\n",
      "\n",
      "üü© FIELD: Gender based\n",
      "üîç Matched Paragraph:\n",
      " Women in the following categories are considered WONCBP:\n",
      "üìù Summary:\n",
      " Women of Non-Childbearing Potential (WONCBP) are defined as females who meet specific criteria excluding them from the potential to conceive.\n",
      "\n",
      "üü© FIELD: Age Limits\n",
      "üîç Matched Paragraph:\n",
      " Male or female 18 to 65 years, at the time of signing the informed consent form.\n",
      "üìù Summary:\n",
      " 18-65\n",
      "\n",
      "üü© FIELD: Age ranges (EU only)\n",
      "üîç Matched Paragraph:\n",
      " Male or female 18 to 65 years, at the time of signing the informed consent form.\n",
      "üìù Summary:\n",
      " 18-65\n",
      "\n",
      "üü© FIELD: Accepts healthy volunteers\n",
      "üîç Matched Paragraph:\n",
      " Not applicable as this is a healthy volunteer study.\n",
      "üìù Summary:\n",
      " Yes\n",
      "\n",
      "üü© FIELD: Study population types (EU only)\n",
      "üîç Matched Paragraph:\n",
      " STUDY POPULATION\n",
      "üìù Summary:\n",
      " Summary:  \n",
      "The study population consists of individuals from the European Union (EU) categorized into specific types, including healthy volunteers, patients with pre-existing conditions, and individuals undergoing specific medical treatments.\n",
      "\n",
      "üü© FIELD: Inclusion criteria\n",
      "üîç Matched Paragraph:\n",
      " Inclusion criteria\n",
      "üìù Summary:\n",
      " Summary:  \n",
      "Patients aged 18‚Äì65 years with a confirmed diagnosis of the target condition, able to provide informed consent, and willing to comply with study procedures were included.\n",
      "\n",
      "üü© FIELD: Exclusion criteria\n",
      "üîç Matched Paragraph:\n",
      " Exclusion criteria\n",
      "üìù Summary:\n",
      " Patients were excluded if they had a history of severe allergic reactions, uncontrolled chronic illnesses, active infections, pregnancy, or were under 18 years of age.\n",
      "\n",
      "üü© FIELD: Study Termination / Cancellation\n",
      "üîç Matched Paragraph:\n",
      " For study termination:\n",
      "üìù Summary:\n",
      " The study was terminated due to [reason for termination, e.g., lack of participant enrollment, safety concerns, or insufficient funding].\n",
      "\n",
      "üü© FIELD: Recruitment status\n",
      "üîç Matched Paragraph:\n",
      " Recruitment strategy\n",
      "üìù Summary:\n",
      " Recruitment status: Recruitment is ongoing.\n",
      "\n",
      "üü© FIELD: Why study stopped\n",
      "üîç Matched Paragraph:\n",
      " Discontinuation of study intervention\n",
      "üìù Summary:\n",
      " The study intervention was discontinued due to safety concerns and adverse events observed in participants.\n",
      "\n",
      "üü© FIELD: Investigational New Drug Application (IND)/Investigational Device Exemption (IDE) Information\n",
      "üîç Matched Paragraph:\n",
      " The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.\n",
      "üìù Summary:\n",
      " The Investigator is responsible for conducting or coordinating supplemental assessments, including laboratory tests, histopathological examinations, or consultations, as needed to clarify the nature and causality of AEs or SAEs, either medically indicated or requested by the Sponsor.\n",
      "\n",
      "üü© FIELD: U.S. FDA IND/IDE study\n",
      "üîç Matched Paragraph:\n",
      " Appendix 1: Regulatory, ethical, and study oversight considerations\n",
      "üìù Summary:\n",
      " Summary: The study adheres to U.S. FDA IND/IDE requirements, ensuring compliance with regulatory and ethical standards. Oversight mechanisms are in place to monitor study conduct and integrity.\n",
      "\n",
      "üü© FIELD: FDA center (formerly IND/IDE grantor)\n",
      "üîç Matched Paragraph:\n",
      " That I am aware of and will comply with Good Clinical Practise (GCP) and all applicable regulatory requirements.\n",
      "üìù Summary:\n",
      " FDA center (formerly IND/IDE grantor): Complies with Good Clinical Practice (GCP) and applicable regulatory requirements.\n",
      "\n",
      "üü© FIELD: IND/IDE number\n",
      "üîç Matched Paragraph:\n",
      " An Investigator who receives an Investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file it along with the (IB/ investigational directions for use [IDFU]/package insert or state other documents) and will notify the IRB/IEC, if appropriate according to local requirements.\n",
      "üìù Summary:\n",
      " This paragraph does not contain an IND/IDE number.\n",
      "\n",
      "üü© FIELD: IND serial number\n",
      "üîç Matched Paragraph:\n",
      " Participants will be allocated a unique enrolment number at the study site. This number will be retained regardless of whether the participant subsequently fulfils the eligibility criteria. If a participant withdraws from the study, the enrolment number will not be reused, and the participant will not be allowed to re-enter the study.\n",
      "üìù Summary:\n",
      " No numerical data provided.\n",
      "\n",
      "üü© FIELD: US FDA regulated drug\n",
      "üîç Matched Paragraph:\n",
      " Regulatory and ethical considerations\n",
      "üìù Summary:\n",
      " Summary:  \n",
      "The paragraph discusses regulatory and ethical considerations relevant to the clinical study, including adherence to guidelines for US FDA-regulated drugs. It emphasizes compliance with regulatory requirements and ethical standards to ensure participant safety and data integrity.\n",
      "\n",
      "üü© FIELD: Product exported from US\n",
      "üîç Matched Paragraph:\n",
      " Seroxat [SmPC; Summary of Product Characteristics].¬†Brentford, UK:¬†GSK; 2022.\n",
      "üìù Summary:\n",
      " Seroxat exported from the US to Brentford, UK.\n",
      "\n",
      "üü© FIELD: Availability of expanded access\n",
      "üîç Matched Paragraph:\n",
      " Inclusion criteria\n",
      "üìù Summary:\n",
      " Summary: Expanded access is available for patients who meet inclusion criteria.\n",
      "\n",
      "üü© FIELD: Expanded access record National Clinical Trial (NCT) number\n",
      "üîç Matched Paragraph:\n",
      " 10.1.7.\tDissemination of Clinical Study Data\t71\n",
      "üìù Summary:\n",
      " 71\n",
      "\n",
      "üü© FIELD: Plan to share IPD data\n",
      "üîç Matched Paragraph:\n",
      " The participant must be informed that their personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant, that their data will be used as described in the informed consent.\n",
      "üìù Summary:\n",
      " Participant data will be shared in compliance with local data protection laws and as outlined in the informed consent.\n",
      "\n",
      "üü© FIELD: url\n",
      "üîç Matched Paragraph:\n",
      " PAGE\n",
      "üìù Summary:\n",
      " PAGE\n"
     ]
    }
   ],
   "source": [
    "final_summaries = {}\n",
    "\n",
    "for field, paragraph in matched_paragraphs.items():\n",
    "    print(f\"\\nüü© FIELD: {field}\")\n",
    "    print(\"üîç Matched Paragraph:\\n\", paragraph)\n",
    "\n",
    "    summary = summarize_field(field, paragraph)\n",
    "    print(\"üìù Summary:\\n\", summary)\n",
    "\n",
    "    final_summaries[field] = summary\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aa5f6337",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"final_summaries.json\", \"w\") as f:\n",
    "    json.dump(final_summaries, f, indent=2)\n",
    "\n",
    "upload_file(\"final_summaries.json\", \"RawOutputFiles\", \"raw-output\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "77e084d9",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "3.10.12",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
